BR100 Increased By (1.02%)
BR30 Increased By (1.71%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.65%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.75 Decreased By ▼ -0.25 (-0.47%)
BOP 34.25 Increased By ▲ 0.26 (0.76%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.34 Increased By ▲ 0.14 (1.15%)
FCCL 53.89 Increased By ▲ 1.06 (2.01%)
FCSC 5.22 Increased By ▲ 0.15 (2.96%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.11 Increased By ▲ 0.09 (1.12%)
KOSM 5.38 Decreased By ▼ -0.14 (-2.54%)
MLCF 88.05 Increased By ▲ 1.54 (1.78%)
NBP 186.48 Increased By ▲ 1.32 (0.71%)
PACE 10.72 Increased By ▲ 0.14 (1.32%)
PAEL 39.94 Increased By ▲ 0.52 (1.32%)
PIAHCLA 26.17 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 232.78 Increased By ▲ 4.60 (2.02%)
PRL 34.95 Increased By ▲ 0.27 (0.78%)
PTC 67.56 Increased By ▲ 2.23 (3.41%)
SEARL 90.93 Increased By ▲ 0.80 (0.89%)
SSGC 27.17 Increased By ▲ 0.57 (2.14%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.13 Increased By ▲ 1.63 (2.79%)
TPLP 8.76 Increased By ▲ 0.54 (6.57%)
TREET 24.54 Increased By ▲ 0.01 (0.04%)
TRG 71.75 Increased By ▲ 2.04 (2.93%)
WAVES 9.98 Increased By ▲ 0.04 (0.4%)
WTL 1.26 Decreased By ▼ -0.02 (-1.56%)
Business & Finance

Different age rules for Oxford/AstraZeneca COVID-19 vaccine in EU

  • Some EU countries, though, have limited its use to people under 65 because of a lack of data for older people in clinical trials for the shot.
  • Countries that have recommended the vaccine's use for people between 18 and 64 years old:
Published February 8, 2021 Updated February 8, 2021 08:38pm
By

The European Medicines Agency last month approved the COVID-19 vaccine developed by AstraZeneca and Oxford University for people over 18 years old.

Some EU countries, though, have limited its use to people under 65 because of a lack of data for older people in clinical trials for the shot.

British regulators have received extra trial data from AstraZeneca supporting their view that the vaccine is effective in the elderly, a vaccines official said on Friday.

The following lists which EU member states' health authorities have so far issued specific age-related recommendations for the British vaccine.

Countries that have recommended the vaccine's use for people between 18 and 64 years old:

AUSTRIA

DENMARK: Health authority said it recommends using the vaccine for people under 65 for now until more data on efficacy among elderly is available.

FRANCE: The Haute Autorite de la Sante (HAS) said people aged 50 to 65 with health issues and medical staff should get priority access.

GERMANY

ICELAND: Iceland, which is a member of the European Free Trade Association, will not be administering the vaccine to people above the age of 65, according to Icelandic media.

NORWAY

PORTUGAL: Portugal's health ministry said the vaccine should preferably be used on under-65s, but that a vaccination for someone older should not be delayed if the AstraZeneca shot is the only one available.

Countries that have given different age-related recommendations:

ITALY: Recommends preferential use of the vaccine for adults aged 55 and under.

POLAND: Will use the vaccine only for people aged 18-60

SPAIN: Approved the vaccine for use in people aged 18 to 55

Sources: Reuters reporting, company press releases, regulatory bodies.

Comments

Comments are closed for this article.